Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Pulmonary Arterial Remodeling and RV Afterload
2026-09-11
The 2025 reference study uses a subject-specific one-dimensional fluid–structure interaction model to separate how distal resistance and proximal arterial compliance shape pulmonary hypertension hemodynamics. Its central finding is that resistance most strongly elevates maximum main pulmonary artery pressure, whereas reduced compliance substantially increases characteristic impedance, providing a quantitative framework for interpreting right ventricular afterload.
-
In Vitro Drug Response: Arrest Versus Cell Death
2026-09-10
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central practical contribution is a two-dimensional framework that separates growth inhibition from cell killing and emphasizes their different magnitudes and timing in vitro.
-
HDAC3–NRF2–GPX4 Control of Ferroptosis in CRC
2026-09-10
A 2025 study identifies HDAC3 as an epigenetic suppressor of ferroptosis in colorectal cancer cells and defines an HDAC3–NRF2–GPX4 signaling axis that preserves ferroptosis resistance. Its combined pharmacological, genetic, and rescue experiments provide a framework for interpreting how antioxidant transcriptional programs influence ferroptosis sensitivity.
-
Aurora A in Retinoblastoma: Evidence for Targeted Therapy
2026-09-09
A 2024 American Journal of Pathology study identifies AURKA overexpression as a frequent feature of retinoblastoma and links it to histopathologic factors associated with aggressive disease. By combining patient specimens with genetic, pharmacologic, patient-derived, and xenograft models, the study provides a mechanistic rationale for targeting Aurora A in high-risk retinoblastoma while defining important translational limitations.
-
N-octanoyl-L-Homoserine lactone Workflows
2026-09-09
Build reproducible C8-HSL assays for quorum sensing, biofilm formation regulation, and host-cell signaling. This guide connects practical dosing and controls with emerging evidence linking bacterial communication to lung cancer cell behavior.
-
MLN2238: Proteasome β5 Subunit Inhibitor Guide
2026-09-08
MLN2238 combines nanomolar chymotrypsin-like proteasome inhibition with a reversible mechanism suited to time-course, washout, and resistance studies. This guide translates its use from Drosophila stress-response assays into practical workflows for multiple myeloma, lymphoma, apoptosis, and proteostasis research.
-
(5Z)-7-Oxozeaenol TAK1 Inhibitor Workflow
2026-09-08
Build a cleaner TAK1 signaling workflow with (5Z)-7-Oxozeaenol, from IL-1-driven inflammation assays to metabolic-stress experiments. Its nanomolar potency, reported pathway selectivity, and compatibility with NF-κB, JNK/p38, COX-2, AMPK, and SQSTM1 readouts make it useful for mechanism-focused studies rather than endpoint-only screening.
-
Biotin (Vitamin B7) for STING Assay Design
2026-09-07
Biotin and Vitamin B7 are more than metabolic cofactors or labeling handles. This article explains how to use biotin chemistry to build interpretable STING and antiviral assays without confusing molecular capture with pathway activation.
-
Drug Response Metrics in Cancer In Vitro
2026-09-07
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable readouts of anticancer activity. Its central practical contribution is a framework for separating growth inhibition from cell killing, improving interpretation of drug-response experiments and apoptosis-focused studies.
-
Latrunculin B: Actin Dynamics Workflow Guide
2026-09-05
Latrunculin B provides a transient way to interrupt actin filament assembly, making it useful for time-resolved cytoskeletal organization studies rather than long exposures. This guide combines practical dosing, imaging controls, and a reference-study case in which actin disruption did not block grass carp reovirus entry.
-
Hypoxia and Immunometabolism in Tumors
2026-09-04
The 2025 Cancer Letters review by Wu and colleagues presents tumor hypoxia as an ecosystem-level driver that links metabolic reprogramming, nutrient competition, immune dysfunction, and immunosuppressive microenvironment formation. Its practical value lies in integrating oxygen biology with immune-cell metabolism and identifying experimental and therapeutic strategies that account for this bidirectional interaction.
-
Hyaluronic Acid Sodium Salt in siRNA Workflows
2026-09-04
Hyaluronic acid sodium salt provides a practical high-molecular-weight matrix material for nanoparticle coating, extracellular matrix modeling, and immune-cell assays. This guide translates a preclinical TDRD9-siRNA study into reproducible formulation, cell-based, organoid, and troubleshooting workflows.
-
BAF53a, EMT, and Glioma Invasion: Study Analysis
2026-09-03
Meng et al. identify BAF53a as a candidate independent prognostic biomarker in glioma and connect its expression to increased proliferation, motility, invasion, and EMT-associated marker changes. The study combines patient-tissue analysis with gain- and loss-of-function experiments in U87 cells, providing a mechanistic basis for further validation rather than definitive clinical translation.
-
Bazedoxifene: Reliable ER Assay Workflows
2026-09-03
Learn how Bazedoxifene (SKU A3232) can be integrated into estrogen receptor, viability, and proliferation experiments without confusing receptor antagonism with nonspecific cytotoxicity. This scenario-driven guide covers controls, solvent compatibility, protocol planning, interpretation, and practical supplier selection.
-
Gastrin I: Designing Translational GI Assays
2026-09-02
Discover how human Gastrin I peptide can be used as a compartment-aware perturbation tool across gastric signaling and human intestinal organoid workflows. This article translates recent hiPSC-organoid advances into practical assay design, controls, and interpretation strategies.